Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

DS Owers, AC Webster, GFM Strippoli… - Cochrane database …, 2013 - cochranelibrary.com
Background Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid
organ transplant recipients. Pre‐emptive treatment of patients with CMV viraemia using …
被引用次数：143 相关文章
[PDF] core.ac.uk

[PDF][PDF] Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

DS Owers, AC Webster, GFM Strippoli… - status and date: New …, 2013 - core.ac.uk
Background Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid
organ transplant recipients. Pre-emptive treatment of patients with CMV viraemia using …

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.

DS Owers, AC Webster, GF Strippoli… - The Cochrane …, 2013 - europepmc.org
Background Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid
organ transplant recipients. Pre-emptive treatment of patients with CMV viraemia using …

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

DS Owers, AC Webster… - The Cochrane …, 2013 - pubmed.ncbi.nlm.nih.gov
Background Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid
organ transplant recipients. Pre-emptive treatment of patients with CMV viraemia using …
[PDF] academia.edu

[PDF][PDF] Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

DS Owers, AC Webster, GFM Strippoli… - status and date: New …, 2013 - academia.edu
Background Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid
organ transplant recipients. Pre-emptive treatment of patients with CMV viraemia using …

Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

DS Owers, AC Webster, GFM Strippoli, K Kable… - 2013 - ses.library.usyd.edu.au
Background Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid
organ transplant recipients. Pre‐emptive treatment of patients with CMV viraemia using …

Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

DS Owers, AC Webster, GFM Strippoli… - Cochrane Database …, 1996 - cochranelibrary.com
Background Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid
organ transplant recipients. Pre‐emptive treatment of patients with CMV viraemia using …
[HTML] nih.gov

[HTML][HTML] Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

DS Owers, AC Webster, GFM Strippoli… - The Cochrane …, 2013 - ncbi.nlm.nih.gov
Background Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid
organ transplant recipients. Pre‐emptive treatment of patients with CMV viraemia using …

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

DS Owers, AC Webster, G Strippoli, K Kable… - COCHRANE …, 2013 - ricerca.uniba.it
BackgroundCytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid
organ transplant recipients. Pre-emptive treatment of patients with CMV viraemia using …